Gastrin is the major ligand activating the CCK-BR and because PAS therapy induces neutralizing gastrin antibodies and gastrin-activated memory T cells (31), the ability to decrease signaling at this receptor is central to inhibiting cancer growth. Here, GAST is linked to cancer.